Pharma Mar, S.A. (PHM.MC) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. PHM.MC files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.64% | 30.00% | Pass |
| Interest-bearing investments | 11.66% | 30.00% | Pass |
| Non-permissible income | 1.40% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.23% | 33.00% | Pass |
| Interest-bearing investments | 42.33% | 33.00% | Fail |
| Non-liquid assets | 47.79% | at least 20.00% | Pass |
| Non-permissible income | 1.40% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.23% | 33.33% | Pass |
| Cash + interest-bearing securities | 42.33% | 33.33% | Fail |
| Accounts receivable | 52.21% | 33.33% | Fail |
| Non-permissible income | 1.40% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 13.23% | 33.33% | Pass |
| Cash + interest-bearing securities | 42.33% | 33.33% | Fail |
| Accounts receivable | 52.21% | 50.00% | Fail |
| Non-permissible income | 1.40% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.46% | 33.00% | Pass |
| Cash + interest-bearing securities | 11.06% | 33.00% | Pass |
| Accounts receivable | 2.58% | 33.00% | Pass |
| Non-permissible income | 1.40% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.26% | 33.00% | Pass |
| Cash + interest-bearing securities | 13.63% | 49.00% | Pass |
| Accounts receivable | 3.18% | 49.00% | Pass |
| Non-permissible income | 1.40% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.26% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.63% | 33.33% | Pass |
| Accounts receivable | 16.81% | 49.00% | Pass |
| Non-permissible income | 1.40% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 34.10 | NEUTRAL |
| Stochastic %K (14) | 4.86 | BUY |
| CCI (20) | -227.77 | BUY |
| Williams %R (14) | -95.14 | BUY |
| MACD (12,26,9) | -0.88 | SELL |
| ROC (10) | -8.73 | SELL |
| Momentum (10) | -7.30 | SELL |
| EMA (10) | 80.03 | SELL |
| SMA (10) | 80.87 | SELL |
| EMA (20) | 80.84 | SELL |
| SMA (20) | 81.99 | SELL |
| EMA (30) | 80.88 | SELL |
| SMA (30) | 81.28 | SELL |
| EMA (50) | 81.06 | SELL |
| SMA (50) | 80.25 | SELL |
| EMA (100) | 81.94 | SELL |
| SMA (100) | 84.21 | SELL |
| EMA (200) | 81.29 | SELL |
| SMA (200) | 82.13 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2024-12-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.